| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1097/00008571-199808000-00001 |
| P698 | PubMed publication ID | 9731714 |
| P2093 | author name string | B K Tang | |
| W Kalow | |||
| L Endrenyi | |||
| P433 | issue | 4 | |
| P304 | page(s) | 283-289 | |
| P577 | publication date | 1998-08-01 | |
| P1433 | published in | Pharmacogenetics and Genomics | Q10534561 |
| P1476 | title | Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research | |
| P478 | volume | 8 |
| Q92107770 | A comprehensive review of computational techniques for the prediction of drug side effects |
| Q52278603 | A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. |
| Q24622468 | A genome-wide association study of carotid atherosclerosis in HIV-infected men |
| Q36412046 | Analysis of genetic variations in CYP2C9, CYP2C19, CYP2D6 and CYP3A5 genes using oligonucleotide microarray |
| Q38542847 | Asthma Pharmacogenomics: 2015 Update |
| Q35076452 | Asthma pharmacogenetics and the development of genetic profiles for personalized medicine |
| Q37686203 | Bernard Lerer: recipient of the 2014 inaugural Werner Kalow Responsible Innovation Prize in Global Omics and Personalized Medicine (Pacific Rim Association for Clinical Pharmacogenetics). |
| Q27015878 | Biomarkers for ischemic preconditioning: finding the responders |
| Q27004404 | Biomarkers for stroke |
| Q37430515 | Bone mass pharmacogenetics and ethnic health implications |
| Q38093137 | Cancer pharmacogenomics in children: research initiatives and progress to date. |
| Q36335956 | Concept-based learning of personalized prescribing |
| Q36450756 | Concordance of DMET plus genotyping results with those of orthogonal genotyping methods |
| Q35929617 | ERCC1 C118T associates with response to FOLFOX4 chemotherapy in colorectal cancer patients in Han Chinese |
| Q34255499 | Effect of gene polymorphisms on the levels of calcineurin inhibitors in Indian renal transplant recipients |
| Q39803558 | Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin |
| Q40492876 | Evaluation of effects of thymidylate synthase and excision repair cross-complementing 1 polymorphisms on chemotherapy outcome in patients with gastrointestinal tumors using peripheral venous blood |
| Q55246416 | Evaluation of person-level heterogeneity of treatment effects in published multiperson N-of-1 studies: systematic review and reanalysis. |
| Q37117267 | GENETIC VARIATION IN THE β(2)-ADRENERGIC RECEPTOR: IMPACT ON INTERMEDIATE CARDIOVASCULAR PHENOTYPES |
| Q47224501 | Gender differences in clinical registration trials; is there a real problem? |
| Q56981756 | Genetic Influences on the Pharmacokinetics of Orally and Intravenously Administered Digoxin as Exhibited by Monozygotic Twins |
| Q36354529 | Genetic Polymorphisms Analysis of Pharmacogenomic VIP Variants in Miao Ethnic Group of Southwest China. |
| Q48744224 | Genetic polymorphisms of NAD(P)H oxidase: variation in subunit expression and enzyme activity. |
| Q35868053 | Genetic susceptibility to tobacco-related cancer |
| Q36635088 | Genetics of inflammatory bowel disease: current status and future directions |
| Q36218993 | Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium |
| Q38292930 | Genomic architecture of pharmacological efficacy and adverse events |
| Q40628246 | Heritability of Caffeine Metabolism: Environmental Effects Masking Genetic Effects on CYP1A2 Activity but Not on NAT2. |
| Q41398712 | Heritability of metoprolol and torsemide pharmacokinetics |
| Q48202910 | INFLUENCE OF PHARMACOGENETIC POLYMORPHISMS AND DEMOGRAPHIC VARIABLES ON METFORMIN PHARMACOKINETICS IN AN ADMIXED BRAZILIAN COHORT. |
| Q30383865 | Impact of germline and somatic missense variations on drug binding sites |
| Q41630307 | Impact of nonsynonymous single nucleotide polymorphisms on in-vitro metabolism of exemestane by hepatic cytosolic reductases |
| Q37433329 | Implementing Pharmacogenomics at Your Institution: Establishment and Overcoming Implementation Challenges |
| Q33777963 | In vitro metabolism of exemestane by hepatic cytochrome P450s: impact of nonsynonymous polymorphisms on formation of the active metabolite 17β-dihydroexemestane |
| Q35925122 | Individual response to treatment: is it a valid assumption? |
| Q28070574 | Individualization of antiretroviral therapy--pharmacogenomic aspect |
| Q99711636 | Inherited and Acquired Determinants of Hepatic CYP3A Activity in Humans |
| Q84805411 | Investigating variability in patient response to treatment – a case study from a replicate cross-over study |
| Q39204093 | Low heritability in pharmacokinetics of talinolol: a pharmacogenetic twin study on the heritability of the pharmacokinetics of talinolol, a putative probe drug of MDR1 and other membrane transporters |
| Q40490138 | Mastering variation: variance components and personalised medicine. |
| Q33720712 | Measuring the overall genetic component of nevirapine pharmacokinetics and the role of selected polymorphisms: towards addressing the missing heritability in pharmacogenetic phenotypes? |
| Q35988128 | Microfluidic platform for single nucleotide polymorphism genotyping of the thiopurine S-methyltransferase gene to evaluate risk for adverse drug events |
| Q36219923 | Molecular biomarkers of colorectal cancer: prognostic and predictive tools for clinical practice |
| Q36786517 | Molecular studies of major depressive disorder: the epigenetic perspective |
| Q34550417 | Next-Generation Sequencing in Oncology: Genetic Diagnosis, Risk Prediction and Cancer Classification. |
| Q36097060 | Personalized therapy for pancreatic cancer: Myth or reality in 2010? |
| Q34938911 | Personalizing health care: feasibility and future implications |
| Q34088287 | Pharmacogenetics and adverse drug reactions |
| Q37425660 | Pharmacogenetics and the development of personalized approaches for combination therapy in asthma |
| Q33842599 | Pharmacogenetics of antipsychotic treatment: lessons learned from clozapine |
| Q23919667 | Pharmacogenetics, pharmacogenomics, and individualized medicine |
| Q37600573 | Pharmacogenetics: implications of race and ethnicity on defining genetic profiles for personalized medicine |
| Q28392069 | Pharmacogenomics and Global Precision Medicine in the Context of Adverse Drug Reactions: Top 10 Opportunities and Challenges for the Next Decade |
| Q34297575 | Pharmacogenomics and individualized medicine: translating science into practice |
| Q27692687 | Pharmacogenomics of Drug Metabolizing Enzymes and Transporters: Relevance to Precision Medicine |
| Q35135951 | Pharmacogenomics--how close/far are we to practising individualized medicine for children? |
| Q37646842 | Pharmacogenomics: a new paradigm to personalize treatments in nephrology patients. |
| Q92776536 | Pharmacomicrobiomics: The Holy Grail to Variability in Drug Response? |
| Q55007103 | Pharmacomicrobiomics: a novel route towards personalized medicine? |
| Q92798933 | Potential role of pharmacogenomics testing in the setting of enhanced recovery pathways after surgery |
| Q37082500 | Promises and challenges of pharmacogenetics: an overview of study design, methodological and statistical issues |
| Q80515695 | Remission and regression of diabetic nephropathy |
| Q24617125 | Role of Statistical Random-Effects Linear Models in Personalized Medicine |
| Q36441540 | Role of pharmacogenomics in the treatment of tuberculosis: a review |
| Q35670196 | SNPs in cancer research and treatment |
| Q45869049 | Search for genetic determinants of sulfonylurea efficacy in type 2 diabetic patients from China. |
| Q35891594 | Second malignancies after multiple myeloma: from 1960s to 2010s |
| Q36000004 | Special populations and pharmacogenetic issues in tuberculosis drug development and clinical research |
| Q36053773 | Tacrine is not an ideal probe drug for measuring CYP1A2 activity in vivo |
| Q44414314 | Tardive dyskinesia is not associated with the polymorphisms of 5-HT2A receptor gene, serotonin transporter gene and catechol-o-methyltransferase gene ⋆ |
| Q36996178 | Testing gene-treatment interactions in pharmacogenetic studies |
| Q38200683 | The emerging era of pharmacogenomics: current successes, future potential, and challenges |
| Q53692809 | The role of the ADRA2A C1291G genetic polymorphism in response to dexmedetomidine on patients undergoing coronary artery surgery. |
| Q39145520 | Through a glass darkly: economics and personalised medicine |
| Q49487177 | Treatment-related acute granulocyte-monocytic leukemia from multiple myeloma: A case report and literature review. |
| Q43284930 | UGT1A1, UGT1A6 and UGT1A7 genetic analysis: repercussion for irinotecan pharmacogenetics in the São Miguel Island Population (Azores, Portugal). |
| Q36209872 | Understanding Variation in Sets of N-of-1 Trials |
| Q84176010 | Using patient DNA to optimize therapy in heart failure patients: a move toward perfection |
| Q37621615 | Using systems approaches to address challenges for clinical implementation of pharmacogenomics. |
| Q90590235 | Variability and Heritability of Thiamine Pharmacokinetics With Focus on OCT1 Effects on Membrane Transport and Pharmacokinetics in Humans |
| Q34172972 | What will be the role of pharmacogenetics in evaluating drug safety and minimising adverse effects? |
| Q37826340 | Why, when, and how should pharmacogenetics be applied in clinical studies?: current and future approaches to study designs |
| Q79437519 | [Pharmacogenetics I. Concept, history, objectives and areas of study] |
Search more.